INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Werte in diesem Artikel
NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether argenx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On June 30, 2025, the U.S. Food and Drug Administration ("FDA") issued an alert on a potential signal of serious risks associated with argenx's Vyvgart Hytrulo product, stating that the treatment has a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" based on reports to the FDA Adverse Event Reporting System. The alert also said that the "FDA is evaluating the need for regulatory action."
On this news, argenx's American Depositary Share ("ADS") price fell $8.92 per ADS, or 1.59%, to close at $551.22 per ADS on June 30, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-argenx-se---argx-302501969.html
SOURCE Pomerantz LLP
Ausgewählte Hebelprodukte auf arGEN-X
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf arGEN-X
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle arGEN-X Aktie News
arGEN-X Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für arGEN-X nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.12.18 | arGEN-X SE (spons ADRs) Outperform | Wolfe Research |
